Investor Presentaiton

For personal use only Contents Executive summary Offer details Company and programs overview IlluccixⓇ imaging Prostate cancer therapy Renal cancer program Rare diseases program Future value creation Key risks International selling restrictions Telix Pharmaceuticals Limited (ASX: TLX) 4 9 13 21 27 38 45 51 55 58 3 TELIX PHARMACEUTICALS

View entire presentation